Welcome to our dedicated page for uniQure N.V. SEC filings (Ticker: QURE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on uniQure N.V.'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into uniQure N.V.'s regulatory disclosures and financial reporting.
uniQure N.V. director Jack Kaye exercised stock options and sold the resulting shares in a coordinated transaction. On June 17, 2026, he exercised options for 5,295 Ordinary Shares at $31.71 per share and then sold the same 5,295 shares in the open market at a weighted average price of $42.57, under a pre-arranged Rule 10b5-1 trading plan adopted on June 16, 2025.
Following these transactions, Kaye directly holds 25,996 Ordinary Shares of uniQure. The exercised stock option, which vested in full on January 25, 2020 and had an expiration date of January 25, 2029, now shows zero remaining derivative balance.
uniQure N.V. reported preliminary six-month data from the first, low-dose cohort in its Phase I/IIa trial of AMT-260 for refractory mesial temporal lobe epilepsy. Three of six patients showed meaningful reductions in disabling seizures between months four and six, with declines of 79% to 100% from baseline.
The other three patients had mixed results, ranging from a 33% decrease to a 36% increase in disabling seizures over the same period. AMT-260 was generally well-tolerated, with no serious adverse events related to the therapy or surgery, only mild to moderate side effects such as headache, and no need for immunosuppression.
uniQure N.V. reported an insider sale filing indicating planned and recent dispositions of Ordinary Shares by Matthew C. Kapusta. The filing lists 41,671 shares associated with Citigroup Global Markets on 06/18/2026, 37,015 shares labeled "Vested Stock from PSU and RSU" to be sold on 06/18/2026, and a separate "Stock option exercise and sale" of 4,656 shares on 06/18/2026. The filing also records actual sales in the prior three months: 152,844 shares sold on 06/17/2026 for $6,724,136.05 and 11,585 shares sold on 06/18/2026 for $563,610.25.
UniQure N.V. reported Form 144 sales of Ordinary Shares on 06/17/2026 through Citigroup Global Markets. The filing lists 101,848 shares described as vested PSU/RSU sales pursuant to a Rule 10b5-1 plan and 62,581 shares from a stock option exercise and sale pursuant to a Rule 10b5-1 plan. The broker is Citigroup Global Markets and the transactions are marked as cash and compensation related.
uniQure N.V. director Balachandran Madhavan reported an exercise-and-sell transaction in Ordinary Shares. He exercised stock options for 10,000 shares at $8.49 per share and sold 10,000 shares in an open-market transaction at a weighted average price of $27.85 per share. After these transactions, he directly holds 43,254 Ordinary Shares. The filing notes the sales were made under a pre-arranged Rule 10b5-1 trading plan adopted on March 10, 2026, and that the sale prices ranged from $27.58 to $28.05.
uniQure N.V. Chief Legal Officer Jeannette Potts reported an open-market sale of 5,237 ordinary shares at a weighted average price of about $27.67 per share. The shares were sold automatically upon RSU vesting solely to cover estimated withholding taxes, and she continues to hold 133,246 shares directly.
UniQure N.V. submitted a Form 144 notice to sell 5,295 Ordinary Shares on 06/17/2026 pursuant to a stock option exercise under a 10b5-1 plan. The proposed sale lists Citigroup Global Markets, Inc. as the broker and indicates cash proceeds.
The filing also reports two recent dispositions by Jack Kaye: 2,645 shares sold on 06/03/2026 for $79,384.35 and 1,993 shares sold on 06/11/2026 for $53,938.39.
UniQure N.V. reported Section 144 sale notices for Ordinary Shares executed on 06/17/2026 pursuant to a 10b5-1 plan. The filing lists a sale method as stock option exercise and sale for 11,685 shares with cash proceeds. The excerpt also shows prior sales by Balachandran Madhavan on 06/11/2026 (1,993 shares) and 06/15/2026 (10,000 shares).
uniQure N.V. reported that the U.S. FDA has indicated the 3-year analysis from its Phase I/II study of AMT-130 in Huntington’s disease can serve as the primary basis of a Biologics License Application for accelerated approval. Based on this feedback, the company plans to submit a BLA for AMT-130 in the third quarter of 2026, targeting patients with early manifest Huntington’s disease.
Before submission, uniQure and FDA aim to align on the design of a required confirmatory study, potentially using a concurrent standard-of-care control instead of a sham procedure. AMT-130 already holds RMAT, Breakthrough Therapy and Fast Track designations, underscoring regulatory focus on a serious disease with no approved disease-modifying therapies.
uniQure N.V. reported results from its 2026 annual meeting, where shareholders approved all proposals on the agenda. They adopted an amendment to the 2014 Share Incentive Plan to increase the number of ordinary shares reserved for equity compensation, following prior approval by the board.
Shareholders also approved amendments to the Articles of Association to reflect the Dutch large company regime, increase authorized share capital and ordinary shares, and add a U.S. federal court exclusive‑forum provision for certain disputes. All director reappointments, share issuance and repurchase authorities, auditor appointment, and advisory executive compensation votes received strong support based on the reported tallies.